Over the last 50 years, the shift to value-based medicine has been driven by regulatory bodies to bring about a remarkable confluence of real-world data (RWD) and technology acceleration at pharmaceutical companies. One of the most exciting developments is the number of potential use cases for the application of integrated real-world data across the oncology drug development lifecycle.
Given the rapid pace of innovation, expansion, and adoption; real-world data can no longer be a series of static, one-time purchases. Rather, the new paradigm of insight and real-world evidence (RWE) generation is lifelong and enterprise-level and requires a living dataset that can grow and evolve with the needs of researchers and the patients they serve.
Join Warren Whyte, PhD, Vice President of Scientific Partnerships and Customer Success at ConcertAI, for a live webinar on how “living” datasets work and how such advanced oncology RWD can accelerate an enterprise-level approach to RWE.